WO2021184391A1 - Procédé de criblage précoce du nouveau coronavirus - Google Patents
Procédé de criblage précoce du nouveau coronavirus Download PDFInfo
- Publication number
- WO2021184391A1 WO2021184391A1 PCT/CN2020/080524 CN2020080524W WO2021184391A1 WO 2021184391 A1 WO2021184391 A1 WO 2021184391A1 CN 2020080524 W CN2020080524 W CN 2020080524W WO 2021184391 A1 WO2021184391 A1 WO 2021184391A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cov
- sars
- protein
- kit
- iga
- Prior art date
Links
- 238000012216 screening Methods 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 22
- 241000711573 Coronaviridae Species 0.000 title description 14
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 84
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 239000011324 bead Substances 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims abstract description 18
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 14
- 239000007853 buffer solution Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 40
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 22
- 239000013642 negative control Substances 0.000 claims description 16
- 239000013641 positive control Substances 0.000 claims description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 15
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 15
- 229940098773 bovine serum albumin Drugs 0.000 claims description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 15
- 101710141454 Nucleoprotein Proteins 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 229910052759 nickel Inorganic materials 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 claims description 9
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000000020 Nitrocellulose Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 229920001220 nitrocellulos Polymers 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000004020 luminiscence type Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 6
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 238000004114 suspension culture Methods 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 5
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 229940096437 Protein S Drugs 0.000 claims description 4
- 101710198474 Spike protein Proteins 0.000 claims description 4
- 238000012937 correction Methods 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000011535 reaction buffer Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000014621 translational initiation Effects 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 210000003292 kidney cell Anatomy 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 230000009871 nonspecific binding Effects 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 102100039948 Interferon alpha-5 Human genes 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 36
- 239000003550 marker Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical group [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 abstract 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 description 40
- 239000000523 sample Substances 0.000 description 32
- 230000035945 sensitivity Effects 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 102100031673 Corneodesmosin Human genes 0.000 description 4
- 101710139375 Corneodesmosin Proteins 0.000 description 4
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102220484825 Protein NDRG1_M1A_mutation Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
Definitions
- the present invention relates to the technical field of immunoassays, in particular to an earlier screening method, reagents and kits for SARS-CoV-2 IgA antibodies of novel coronavirus infection pneumonia (new coronary pneumonia).
- coronavirus pneumonia Since December 2019, the new type of coronavirus pneumonia (new crown pneumonia) has been raging. The cumulative number of people infected in China has exceeded 80,000, and the mortality rate has reached 1.4-3.4%.
- New coronary pneumonia usually develops 3-7 days after being infected with SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). The symptoms are mainly fever, dry cough, fatigue, and can also be accompanied by nasal congestion, runny nose, sore throat, myalgia and diarrhea, etc. . Mild patients have no symptoms of pneumonia. Severe patients often develop dyspnea and/or hypoxemia one week after the onset of onset.
- the virus nucleic acid detection reagent was first used for the diagnosis of new coronary pneumonia. Because of its low detection rate, many companies have begun to develop rapid detection kits for SARS-CoV-2IgG and IgM, including colloidal gold method and chemiluminescence immunoassay. The seventh edition of the new coronary pneumonia diagnosis and treatment plan incorporates IgM and IgG serological testing as laboratory diagnostic methods. Currently, the registered products include 11 nucleic acid detection products and 6 antibody detection products.
- the latter include: colloidal gold method new coronavirus (2019-nCoV) antibody detection kit, colloidal gold method new coronavirus (2019-nCoV) IgM Antibody detection kit, magnetic particle chemiluminescence method new coronavirus (2019-nCoV) IgM antibody detection kit, magnetic particle chemiluminescence method new coronavirus (2019-nCoV) IgG antibody detection kit, new type of scientific luminescent particle immunoassay method Coronavirus (2019-nCoV) antibody detection kit.
- SARS-CoV-2 infects the lower respiratory tract, the patient produces less sputum, and there is a high probability that the sample collection will fail with a throat swab.
- the detection rate of nucleic acid detection reagents for new coronary pneumonia is low, and the sensitivity is only 30-50%, which cannot meet the needs of screening all patients.
- IgM and IgG antibodies Measuring the total antibody improves the sensitivity but cannot effectively distinguish which stage of the patient is in the course of the disease and whether it is still infectious.
- the colloidal gold method is simple and quick to detect, but the accuracy is not enough.
- the sensitivity and specificity of chemiluminescence detection of IgM and IgG antibodies are high, but the window period of the two is long. IgM needs to be detected 3-5 days after the onset of onset, and the detection value of IgG needs to increase by more than 4 times during the recovery period to be diagnosed.
- the purpose of the present invention is to avoid the shortcomings of the prior art and provide a kit and reagents for screening new coronavirus infections that can detect SARS-CoV-2 IgA antibodies earlier.
- kits for detecting SARS-CoV-2 IgA antibody for screening new coronavirus infection Provide a kit for detecting SARS-CoV-2 IgA antibody for screening new coronavirus infection.
- the above-mentioned kit for screening for novel coronavirus infection is used for early screening of SARS-CoV-2 IgA antibodies.
- the above kit for screening for novel coronavirus infection is used as the SARS-CoV-2 magnetic bead coating of R1: a magnetic bead coating containing SARS-CoV-2 recombinant antigen-coated trimethylol Aminomethane buffer, pH value is 7.1-7.4;
- R2 anti-human IgA antibody acridinium ester label 2-(N-morpholine) ethanesulfonic acid buffer containing acridinium ester-labeled mouse anti-human IgA monoclonal antibody.
- the SARS-CoV-2 recombinant antigen is a spike protein expressed in a suspension cultured human embryonic kidney cell line HEK293F, referred to as S protein (Spike protein, S protein). ), the amino acid sequence at positions Gln321-Ser591 of the RBD domain was truncated for protein expression;
- the protein expression process is: the SARS-CoV-2 S protein RBD gene is connected to human IgG1 Fc through a TEV restriction site sequence at the C-terminus, and then it is cloned into the mammalian expression vector pTT5 and Kozak is added to the translation initiation region The sequence was then transfected into suspension culture cells HEK293F, using interferon ⁇ -1 as a signal peptide to make HEK293F cells secrete RBD-TEV-Fc fusion protein, and then using Protein A column and nickel column for two purifications; the first purification To use Protein A column to obtain RBD-TEV-Fc fusion protein from the culture supernatant; the second purification is to use TEV enzyme with 6His tag to digest the fusion protein, and then pass the digested products through Protein A column in turn And nickel column to remove Fc, TEV enzymes, and the impurity protein bound to the Protein A column during the first purification, and finally obtain pure RBD protein in the flow-
- the SARS-CoV-2 recombinant antigen is a nucleocapsid protein expressed in bacteria in suspension culture, referred to as N protein, and N protein is a cut of Met1-Ala419 The amino acid sequence at position is expressed;
- the protein expression process is: connect the SARS-CoV-2 N protein gene to the 6His tag at the N end and clone it into the prokaryotic expression vector pET28a, then transform it into E. coli cells BL21 for N protein expression, and then take the broken bacteria and lyse the bacteria. Add 0.5-2.0M sodium chloride to the solution to reduce non-specific binding of protein and nucleic acid, and then pass the lysate through a nickel column.
- the tris buffer contains 0.05-0.2% Tween 20 (v/v), 2-8% bovine serum albumin ( w/v), 0.25-1% Proclin300(v/v);
- 2-(N-morpholine) ethanesulfonic acid buffer contains 0.05-0.2% Tween 20 (v/v), 2-8% bovine serum albumin (w/v), 0.25-1% Proclin 300 (v/v) ).
- the above kit for screening for novel coronavirus infection also contains:
- reaction buffer of R3 phosphate buffer containing goat anti-human IgG antibody, containing 0.05-0.2% Tween 20 (v/v), 2-8% bovine serum albumin (w/v), 0.25- 1% Proclin300(v/v);
- SARS-CoV-2 IgA negative control SARS-CoV-2 IgA negative serum
- SARS-CoV-2 IgA positive control human-derived purified SARS-CoV-2 IgM antibody
- Negative and positive control information card contains the luminescence value of the negative and positive control, which is used for correction during screening.
- the above-mentioned kit for screening for novel coronavirus infection contains:
- Test card It is composed of SARS-CoV-2 IgA test strip and plastic box; the test strip contains nitrocellulose membrane, sample pad, bonding pad, absorbent paper, and PVC board support;
- the nitrocellulose membrane is coated with anti-human-IgA antibody and anti-mouse IgG polyclonal antibody, and the binding pad contains colloidal gold-labeled SARS-CoV-2 antigen.
- the above-mentioned kit for screening for novel coronavirus infection also contains Tris hydrochloric acid buffer as a sample diluent, the pH of the Tris hydrochloric acid buffer is 7.1-7.4, and it contains 0.5-2% bovine serum white Protein (w/v), 0.05-0.2% Tween 20 (v/v), 0.25-1% Proclin 300 (v/v).
- the present invention also provides a use of a reagent for detecting SARS-CoV-2 IgA antibody in preparing the above reagent or kit for screening novel coronavirus infection.
- the kit used for screening the novel coronavirus infection and its detection reagent of the present invention can detect the novel coronavirus.
- Figure 1 is a schematic diagram of the results of serum SARS-CoV-2 IgA antibody levels in patients with new coronary pneumonia and a control group in an experimental example of the present invention.
- Fig. 2 is a graph showing the change trend of SARS-CoV-2 IgA and IgM antibodies with the course of the disease in an experimental example of the present invention.
- a kit for the detection of SARS-CoV-2 IgA antibodies for screening new coronavirus infections for screening new coronavirus infections. Especially for early screening of SARS-CoV-2 IgA antibodies.
- This kit for screening for novel coronavirus infection includes:
- SARS-CoV-2 magnetic bead coating (R1): Tris buffer containing magnetic bead coating of SARS-CoV-2 recombinant antigen, pH 7.1-7.4, containing 0.05 -0.2% Tween 20 (v/v), 2-8% bovine serum albumin (w/v), 0.25-1% Proclin 300 (v/v); magnetic beads are used as the reaction solid phase carrier, and the antigen is used for binding The target antibody in the test substance.
- Anti-human IgA antibody acridinium ester marker (R2): 2-(N-morpholine) ethanesulfonic acid buffer of acridinium ester-labeled mouse anti-human IgA monoclonal antibody, containing 0.05-0.2% Tween 20 (v/v), 2-8% bovine serum albumin (w/v), 0.25-1% Proclin300 (v/v). Combining with the antigen-antibody complex, under alkaline conditions, the acridinium ester can emit light after being excited.
- Reaction buffer (R3) phosphate buffer containing goat anti-human IgG antibody, containing 0.05-0.2% Tween 20 (v/v), 2-8% bovine serum albumin (w/v), 0.25-1% Proclin300 (v/v). Used to adsorb IgG in the sample to be tested to prevent interference.
- SARS-CoV-2 IgA negative control SARS-CoV-2 IgA negative serum.
- SARS-CoV-2 IgA positive control It is a human-derived purified SARS-CoV-2 IgM antibody.
- Negative and positive control information card contains the luminescence value of the negative and positive control, which is used for correction during screening.
- the experiment requires the substrate solution (aqueous solution containing NaOH) and the cleaning solution (phosphate buffer containing surfactant) as general reagents, which are not provided in this kit.
- SARS-CoV-2 IgA turns positive earlier than IgM antibodies, 1-4 days earlier on average. Therefore, the clinical detection of SARS-CoV-2 IgA antibodies can be carried out earlier, and some patients with new coronary pneumonia can be screened and dealt with early.
- SARS-CoV-2 recombinant antigen is in Spike protein (S protein) expressed in suspension cultured human embryonic kidney cell line HEK293F, referred to as S protein, was extracted from the Gln321-Ser591 amino acid sequence of the RBD domain for protein expression.
- S protein Spike protein
- the protein expression process is: the SARS-CoV-2 S protein RBD gene is connected to human IgG1 Fc through a TEV restriction site sequence at the C-terminus, and then it is cloned into the mammalian expression vector pTT5 and Kozak is added to the translation initiation region The sequence was then transfected into suspension culture cells HEK293F, using interferon ⁇ -1 as a signal peptide to make HEK293F cells secrete RBD-TEV-Fc fusion protein, and then using Protein A column and nickel column for two purifications; the first purification To obtain the RBD-TEV-Fc fusion protein from the culture supernatant using the Protein A column; the second purification is to digest the fusion protein with the TEV enzyme with 6His tag, and then flow the digested products through the Protein A column in turn And nickel column to remove Fc, TEV enzymes, and the impurity protein bound to the Protein A column during the first purification, and finally obtain pure RBD protein in the
- the SARS-COV-2 spike RBD protein expressed by this method is intercepted from the Gln321-Ser591 amino acid sequence of the SARS-COV-2 spike protein.
- the coding gene sequence is shown in the following sequence 1, and its amino acid sequence is shown in the following sequence 2.
- Sequence 1 The gene sequence encoding SARS-COV-2 spike RBD in this patent
- the SARS-COV-2 spike RBD protein of this method is secreted and expressed, and the signal peptide used is the IFNA1 (Interferon ⁇ -1) signal peptide, and the Kozak sequence is added to the translation initiation region.
- the C-terminus of the SARS-COV-2 spike RBD protein of this patent is connected to the human IgG1 Fc sequence through a TEV restriction site sequence.
- the expressed fusion protein is named SARS-COV-2-RBD-TEV-Fc, and its gene sequence (including The signal peptide) is shown in the following sequence 3, and the amino acid sequence is shown in the following sequence 4.
- Sequence 3 The gene sequence of the fusion protein SARS-COV-2-RBD-TEV-Fc
- This patent obtains high-purity SARS-COV-2 spike RBD protein through two purifications.
- the protein A column was used to obtain the SARS-COV-2-RBD-TEV-Fc fusion protein from the culture supernatant.
- the fusion protein was digested with TEV enzyme with 6His tag, and the digested products were passed through the protein A column and the nickel column in turn. At this time, the Fc, TEV enzyme, and the protein bound to the Protein A column during the first purification were all removed. After removal, the purified SARS-COV-2 spike RBD protein is finally obtained in the flow through.
- the SARS-CoV-2 recombinant antigen is a nucleocapsid protein expressed in bacteria in suspension culture, referred to as the N protein, and the N protein is expressed by truncating the amino acid sequence at position Met1-Ala 419.
- the protein expression process is: connect the SARS-CoV-2 N protein gene to the 6His tag at the N end and clone it into the prokaryotic expression vector pET28a, then transform it into E. coli cells BL21 for N protein expression, and then take the broken bacteria and lyse the bacteria.
- the SARS-COV-2 N protein expressed in this patent is truncated from the SARS-COV-2 N protein Met1-Ala 419 amino acid sequence.
- the coding gene sequence is shown in the following sequence 5, and its amino acid sequence is shown in the following sequence 6.
- the SARS-COV-2 N protein of this patent is soluble expression in bacteria, with 6His tag connected to its N end, and a nickel column is used to purify the soluble SARS-COV-2 N from the supernatant of the bacterial fragments. At this time, it is purified. A large amount of nucleic acid is bound to the N protein. In order to remove the nucleic acid, ammonium sulfate is added and stirred at room temperature to expose the hydrophobic core of the protein, and then a hydrophobic column is used to further purify the protein. At this time, the nucleic acid is removed. In order to further remove polymers and other impurity proteins, the superdex200 molecular sieve was used to further purify the protein, and finally a high-purity SARS-COV-2 N protein with uniform conformation was obtained.
- the kit of the present invention can detect the SARS-CoV-2 IgA antibody through the clinic earlier, and screen and deal with some patients with new coronary pneumonia early.
- the sensitivity and specificity of the test results of the kit for diagnosing pneumonia reached 99% and 96%, respectively, and it is an excellent test kit.
- This kit for screening for novel coronavirus infection includes:
- SARS-CoV-2 magnetic bead coating (R1): Tris buffer containing magnetic bead coating of SARS-CoV-2 recombinant antigen, pH 7.2, containing 0.1% spit Temperature 20 (v/v), 5% bovine serum albumin (w/v), 0.5% Proclin300 (v/v); magnetic beads are used as the reaction solid phase carrier, and the antigen is used to bind the target antibody in the test object.
- Anti-human IgA antibody acridinium ester marker (R2) 2-(N-morpholine) ethanesulfonic acid buffer solution of acridinium ester-labeled mouse anti-human IgA monoclonal antibody, containing 0.1% Tween 20 (v /v), 5% bovine serum albumin (w/v), 0.5% Proclin300 (v/v). Combining with the antigen-antibody complex, under alkaline conditions, the acridinium ester can emit light after being excited.
- Reaction buffer (R3) phosphate buffer containing goat anti-human IgG antibody, containing 0.1% Tween 20 (v/v), 5% bovine serum albumin (w/v), 0.5% Proclin 300 ( v/v). Used to adsorb IgG in the sample to be tested to prevent interference.
- SARS-CoV-2 IgA negative control SARS-CoV-2 IgA negative serum.
- SARS-CoV-2 IgA positive control It is a human-derived purified SARS-CoV-2 IgM antibody.
- Negative and positive control information card contains the luminescence value of the negative and positive control, which is used for correction during screening.
- the experiment also requires the substrate solution (aqueous solution containing NaOH) and the cleaning solution (phosphate buffer containing surfactant) as general reagents, which are not provided in this kit.
- SARS-CoV-2 IgA turns positive earlier than IgM antibodies, 1-4 days earlier on average. Therefore, the clinical detection of SARS-CoV-2 IgA antibodies can be carried out earlier, and some patients with new coronary pneumonia can be screened and dealt with early.
- the RBD protein was used as a magnetic bead-coated antigen kit for detection, and clinical studies were conducted on 174 patients and 202 control populations, and the serum SARS-CoV-2 IgA antibody levels of patients with new coronary pneumonia and the control group were obtained.
- the results are shown in Figure 1. .
- the IgA level of patients with new coronary pneumonia is significantly higher than that of the control group.
- the trend of SARS-CoV-2 IgA and IgM antibodies with the course of the disease is shown in Figure 2.
- Figure 2 it can be seen that the patient’s SARS-CoV-2 IgA turns positive earlier than IgM antibodies, on average 2(1-4) )sky. Therefore, clinical testing of SARS-CoV-2 and IgA antibodies at the time of patient consultation can diagnose some patients with new coronary pneumonia earlier.
- the N protein was used as a magnetic bead-coated antigen kit for testing.
- a clinical study was conducted on 100 patients with new coronary pneumonia and 100 controls.
- the test results showed that the positive rates of SARS-CoV-2 IgA in patients and controls were respectively 98.9% and 4.2%, there is a significant difference between the two groups.
- the kit described in any one of Examples 1 to 5 was used to detect 10 normal human sera and 10 new coronary pneumonia patients' sera by chemiluminescence immunoassay.
- the magnetic bead coating (R1) Before installing the machine, the magnetic bead coating (R1) needs to be gently turned upside down about 30 times to make the magnetic bead particles evenly dispersed. There is no need to continue mixing after loading the magnetic bead coating (R1) for the first time.
- sample application set the sample type as negative control and positive control respectively, and select SARS-CoV-2 IgA project, negative control and The positive control should be made 2 replicates, and click "Run” after confirming.
- Detection Put the sample in the sample rack (the sample size should be greater than 300 ⁇ L), push it into the sample rack, edit the sample information on the operation interface, select the SARS-CoV-2 IgA project, and click "Run” after confirming.
- the system will perform the following operations:
- the total incubation time is 15 minutes.
- chemiluminescence immunoassay adopts two-step indirect immunoassay.
- the sample to be tested is incubated with the magnetic bead coating. After magnetic separation and washing of unbound substances, the acridinium ester label is added and incubated together. After washing again, the substrate solution is added, and then the luminescence reaction of the acridinium ester is detected.
- the substrate solution is added, and then the luminescence reaction of the acridinium ester is detected.
- the substrate solution is added, and then the luminescence reaction of the acridinium ester is detected.
- the test result is expressed by the critical value index (COI).
- the kit of the present invention can detect 100% of patients with new coronary pneumonia, with accurate detection results and high sensitivity.
- a kit for screening for novel coronavirus infection containing,
- Test card consists of SARS-CoV-2 IgA test strip and plastic box; the test strip contains nitrocellulose membrane, sample pad, binding pad, absorbent paper, PVC board and other supports; the nitrocellulose membrane is coated with anti-human -IgA antibody and anti-mouse IgG polyclonal antibody, the binding pad contains colloidal gold-labeled SARS-CoV-2 antigen, and the method of obtaining the antigen can be the method in Example 2.
- Tris hydrochloric acid buffer of the sample diluent The pH of the Tris hydrochloric acid buffer is 7.1-7.4, containing 0.5-2% bovine serum albumin (w/v), 0.05-0.2% Tween 20 (v/v) , 0.25-1% Proclin300 (v/v). Preferably, it contains 1% bovine serum albumin (w/v), 0.1% Tween 20 (v/v), and 0.5% Proclin 300 (v/v).
- the detection principle of the colloidal gold method is to use the principle of immunochromatographic technology to qualitatively detect SARS-CoV-2 IgA in human serum, plasma, and whole blood.
- the sample contains SARS-CoV-2 IgA
- it is combined with the SARS-CoV-2 CoV-2 antigen binds to form a reaction complex.
- the complex moves forward along the nitrocellulose membrane, and is captured by the anti-human-IgA antibody pre-coated on the detection zone (T) of the nitrocellulose membrane.
- the detection area (T) agglutinates to form a red reaction line visible to the naked eye.
- the result is positive; when the SARS-CoV-2 IgA in the sample is below the minimum detection limit, no red reaction line appears in the detection area (T). The result was negative.
- the kit of Example 1 was used to detect 10 normal human sera and 10 new coronary pneumonia patients with the colloidal gold method.
- Room temperature refers to a temperature of 10°C to 30°C and a humidity of 45% to 75%.
- the kit of the present invention can detect 100% of patients with new coronary pneumonia, with accurate detection results and high sensitivity.
- the present invention also provides the use of a reagent for detecting SARS-CoV-2 IgA antibody in the preparation of the above-mentioned kit for screening new coronavirus infections and the preparation of the reagent for detecting SARS-CoV-2 IgA antibody for screening novel coronavirus infections.
- a reagent for detecting SARS-CoV-2 IgA antibody in the preparation of the above-mentioned kit for screening new coronavirus infections and the preparation of the reagent for detecting SARS-CoV-2 IgA antibody for screening novel coronavirus infections.
- Use of coronavirus infection reagents can detect new coronaviruses, can be used to supplement the diagnosis of new coronary pneumonia at an earlier stage, and has the characteristics of accurate detection results.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/080524 WO2021184391A1 (fr) | 2020-03-20 | 2020-03-20 | Procédé de criblage précoce du nouveau coronavirus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/080524 WO2021184391A1 (fr) | 2020-03-20 | 2020-03-20 | Procédé de criblage précoce du nouveau coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021184391A1 true WO2021184391A1 (fr) | 2021-09-23 |
Family
ID=77767991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/080524 WO2021184391A1 (fr) | 2020-03-20 | 2020-03-20 | Procédé de criblage précoce du nouveau coronavirus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021184391A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11740240B2 (en) | 2020-07-20 | 2023-08-29 | Bio-Rad Laboratories, Inc. | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor |
TWI816315B (zh) * | 2022-03-02 | 2023-09-21 | 慈濟學校財團法人慈濟大學 | 表現新型冠狀病毒sars-cov-2蛋白質的大腸桿菌 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469126A (zh) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | 检测sars冠状病毒抗体的方法及其试剂盒 |
WO2004109289A1 (fr) * | 2003-06-10 | 2004-12-16 | Agency For Science, Technology And Research | Procede pour diagnostiquer une infection par coronavirus du syndrome respiratoire aigu severe (sars) |
WO2005118813A2 (fr) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Acides nucleiques, polypeptides, methodes d'expression, et compositions immunogenes associees a la proteine spike du coronavirus sras |
CN101022827A (zh) * | 2004-06-30 | 2007-08-22 | 魁北克益得生物医学公司 | 用于治疗冠状病毒感染的疫苗组合物 |
CN101575361A (zh) * | 2009-03-20 | 2009-11-11 | 北京健诺威生物科技有限公司 | 新型特异性多肽及其在制备诊断和防治冠状病毒引起的严重急性呼吸综合征药物中的应用 |
CN109001451A (zh) * | 2018-06-06 | 2018-12-14 | 广州市康润生物科技有限公司 | GlyFn化学发光定量检测试剂盒及在早期子痫前期筛查中的用途 |
CN110146692A (zh) * | 2019-05-28 | 2019-08-20 | 迪瑞医疗科技股份有限公司 | 一种基于吖啶酯化学发光、链霉亲和素磁珠-生物素放大反应体系及检测试剂盒 |
-
2020
- 2020-03-20 WO PCT/CN2020/080524 patent/WO2021184391A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469126A (zh) * | 2003-04-26 | 2004-01-21 | 杭州华大基因研发中心 | 检测sars冠状病毒抗体的方法及其试剂盒 |
WO2004109289A1 (fr) * | 2003-06-10 | 2004-12-16 | Agency For Science, Technology And Research | Procede pour diagnostiquer une infection par coronavirus du syndrome respiratoire aigu severe (sars) |
WO2005118813A2 (fr) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Acides nucleiques, polypeptides, methodes d'expression, et compositions immunogenes associees a la proteine spike du coronavirus sras |
CN101022827A (zh) * | 2004-06-30 | 2007-08-22 | 魁北克益得生物医学公司 | 用于治疗冠状病毒感染的疫苗组合物 |
CN101575361A (zh) * | 2009-03-20 | 2009-11-11 | 北京健诺威生物科技有限公司 | 新型特异性多肽及其在制备诊断和防治冠状病毒引起的严重急性呼吸综合征药物中的应用 |
CN109001451A (zh) * | 2018-06-06 | 2018-12-14 | 广州市康润生物科技有限公司 | GlyFn化学发光定量检测试剂盒及在早期子痫前期筛查中的用途 |
CN110146692A (zh) * | 2019-05-28 | 2019-08-20 | 迪瑞医疗科技股份有限公司 | 一种基于吖啶酯化学发光、链霉亲和素磁珠-生物素放大反应体系及检测试剂盒 |
Non-Patent Citations (2)
Title |
---|
DATABASE Protein 18 July 2020 (2020-07-18), ANONYMOUS: "nucleocapsid phosphoprotein [Severe acute respiratory syndrome coronavirus 2]", XP055846541, retrieved from NCBI Database accession no. YP_009724397 * |
DATABASE PROTEIN 18 July 2020 (2020-07-18), ANONYMOUS: "surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]", XP055841491, retrieved from NCBI Database accession no. YP_009724390 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11740240B2 (en) | 2020-07-20 | 2023-08-29 | Bio-Rad Laboratories, Inc. | Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor |
TWI816315B (zh) * | 2022-03-02 | 2023-09-21 | 慈濟學校財團法人慈濟大學 | 表現新型冠狀病毒sars-cov-2蛋白質的大腸桿菌 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112229994B (zh) | 一种基于磁微粒化学发光的新型冠状病毒抗体检测试剂盒 | |
CN108490166B (zh) | 一种改良实验缓冲液及其应用 | |
JP6348553B2 (ja) | HBs抗原を検出するための前処理用試薬キットおよびHBs抗原検出用試薬キット | |
WO2021184391A1 (fr) | Procédé de criblage précoce du nouveau coronavirus | |
CN111537720A (zh) | 一种新型冠状病毒2019-nCoV IgM/IgG抗体联合检测试剂盒的制备方法 | |
WO2022170977A1 (fr) | Anticorps monoclonal de 1,3-bêta-d-glucane antifongique et son utilisation | |
WO2021169664A1 (fr) | Antigène pour un nouveau coronavirus 2019 et utilisation associée pour la détection | |
CN110818800A (zh) | 一种通过构建桥连复合物间接检测目的分析物的检测方法 | |
JP2023017986A (ja) | 自己抗体の直接イムノアッセイ測定法 | |
CN111574608A (zh) | 牛细粒棘球蚴病的特异性检测抗原及其应用 | |
JP6808178B2 (ja) | ヒトパルボウイルスb19抗原および抗体の同時検出方法及びキット | |
JP2019053060A (ja) | B型肝炎ウイルスコア抗体の免疫測定方法 | |
WO2021184390A1 (fr) | Procédé de criblage du nouveau coronavirus 2019 et pré-diagnostic de pneumonie grave sur la base d'indices doubles | |
CN113189333A (zh) | 量子点免疫荧光检测试剂条包含其的试剂盒及其应用 | |
WO2022027703A1 (fr) | Anticorps monoclonal dirigé contre un antigène n du sars-cov-2, son procédé de détection et son utilisation | |
CN114835808B (zh) | 可定向消除假阳性的阻断剂及其制备方法 | |
CN108588030B (zh) | 抗人IgM单克隆抗体、其杂交瘤细胞株及应用 | |
WO2022024925A1 (fr) | Réactif pour test présentant une amélioration du point de vue de l'abaissement de signaux | |
CN108303540B (zh) | 一种猪伪狂犬gE抗体检测试剂盒及其检测方法 | |
KR20230062806A (ko) | 위음성의 억제에 의해 특이성을 개선한 검사 시약 | |
EP4016080A1 (fr) | Nouveau mode de dosage immunologique dans son ensemble pour déterminer un anticorps total | |
JP2006118936A (ja) | メンブランエンザイムイムノアッセイ法 | |
CN109917124A (zh) | 一种丙型肝炎病毒抗原抗体联合检测试剂盒 | |
CN117110603B (zh) | 联合检测抗mcv抗体、抗ccp抗体和rf的荧光免疫层析试纸条 | |
EP4059958A1 (fr) | Anticorps de reconnaissance de protéine n d'antivirus respiratoire syncytial, et procédé ainsi qu'instrument d'immuno-essai mettant en ?uvre cet anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20925908 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20925908 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/04/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20925908 Country of ref document: EP Kind code of ref document: A1 |